Clinical Trial Update: ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial compares ONCONASE plus doxorubicin versus doxorubicin alone in malignant mesothelioma; the current status is not specified.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Mesothelioma

Drugs mentioned

• Doxorubicin (doxorubicin)
• ONCONASE (ranpirnase)

Snippet

Sponsor: Alfacell | Conditions: Malignant Mesothelioma | Phase 3 | Status: UNKNOWN